|
|||||||
|
|
Seattle Structural Genomics Center for Infectious DiseaseSSGCID is one of two Centers recently
funded by NIAID in response to
RFP-NIH-NIAID-DMID-07-19 and is a consortium of four Pacific
Northwest institutions (SeattleBiomed,
Emerald BioStructures, UW, and Pacific Northwest National Laboratory). The other funded center (CSGID)
is based on the East Coast. SSGCID’s primary mission is to
determine the structure of 75-100 protein targets from NIAID
Category A-C agents, as well
as
emerging and re-emerging infectious disease organisms, each
year for a period of five years. What's new?
SSGCID employs a high-throughput gene-to-structure pipeline involving a multi-pronged serial escalation approach to protein expression in bacterial, wheat-germ cell-free translation, baculovirus and mammalian systems followed by structure solution using X-ray crystallography and NMR spectroscopy. Proactive engagement of the infectious disease research and drug therapy communities in the target selection process will help ensure that the resulting protein structures provide a blueprint for structure-based drug design of new therapeutics to combat infectious diseases. This goal will be facilitated by the annual selection of a small number of high-impact targets for a fragment-based drug lead discovery campaign within SSGCID. SSGCID is also committed to providing structural genomics service to the research community and publicly disseminating all structure information and material resources generated as part of the NIAID contract (federal contract nr HHSN272200700057C). In accordance with the requirements of the NIAID contract, SSGCID is working to meet the following project requirements: · Project management and administration · Structure determination pipeline · Structural genomics services to the scientific community · Information dissemination and provision of contract-generated resources
|
||||||
|
|
|||||||